BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 7798304)

  • 21. A phase II trial of paclitaxel in refractory germ cell tumors.
    Sandler AB; Cristou A; Fox S; Williams SD; Nichols CR; Turns M; Roth BJ
    Cancer; 1998 Apr; 82(7):1381-6. PubMed ID: 9529032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
    D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
    Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer.
    Olver I; Davy M; Lüftner D; Park SH; Egorin M; Ellis A; Webster L
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):109-14. PubMed ID: 11561776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer.
    Kollmannsberger C; Gerl A; Schleucher N; Beyer J; Kuczyk M; Rick O; Casper J; Sosada M; Rie C; Kanz L; Bokemeyer C
    Anticancer Drugs; 2000 Aug; 11(7):535-9. PubMed ID: 11036955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy.
    Kollmannsberger C; Mayer F; Kuczyk M; Kanz L; Bokemeyer C
    World J Urol; 2001 Apr; 19(2):120-5. PubMed ID: 11374314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
    Soulié P; Garrino C; Bensmaïne MA; Bekradda M; Brain E; Di Palma M; Goupil A; Misset JL; Cvitkovic E
    J Cancer Res Clin Oncol; 1999 Dec; 125(12):707-11. PubMed ID: 10592105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
    Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
    J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
    Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
    Bokemeyer C; Köhrmann O; Tischler J; Weissbach L; Räth U; Haupt A; Schöffski P; Harstrick A; Schmoll HJ
    Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study.
    Mardiak J; Sálek T; Sycová-Milá Z; Obertová J; Hlavatá Z; Mego M; Recková M; Koza I
    Neoplasma; 2005; 52(6):497-501. PubMed ID: 16284696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of phase II trials of Taxol (paclitaxel) in patients with advanced ovarian cancer.
    Einzig AI
    Ann Oncol; 1994; 5 Suppl 6():S29-32. PubMed ID: 7865430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer.
    Hartmann JT; Kuczyk MA; Kollmannsberger C; Kanz L; Bokemeyer C
    World J Urol; 1999 Oct; 17(5):324-33. PubMed ID: 10552153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors.
    Varuni Kondagunta G; Bacik J; Schwartz L; Sheinfeld J; Bajorin D; Vuky J; Marion S; Mazumdar M; Bosl GJ; Motzer RJ
    Invest New Drugs; 2004 Apr; 22(2):177-9. PubMed ID: 14739666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paclitaxel and cisplatin as salvage treatment in patients with non-seminomatous germ cell tumour who failed to achieve a complete remission on induction chemotherapy.
    Tjulandin SA; Titov DA; Breder VV; Sidorova NJ; Popov AJ; Kupchan DZ; Garin AM
    Clin Oncol (R Coll Radiol); 1998; 10(5):297-300. PubMed ID: 9848329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts.
    Dunn TA; Grünwald V; Bokemeyer C; Casper J
    Invest New Drugs; 1997; 15(2):91-8. PubMed ID: 9220287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
    Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
    Honecker F; Kollmannsberger C; Quietzsch D; Haag C; Schroeder M; Spott C; Hartmann JT; Baronius W; Hempel V; Kanz L; Bokemeyer C
    Anticancer Drugs; 2002 Jun; 13(5):497-503. PubMed ID: 12045461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891.
    Rogers PC; Olson TA; Cullen JW; Billmire DF; Marina N; Rescorla F; Davis MM; London WB; Lauer SJ; Giller RH; Cushing B; ;
    J Clin Oncol; 2004 Sep; 22(17):3563-9. PubMed ID: 15337806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.